Avalo Therapeutics, Inc.

NasdaqCM:AVTX Stock Report

Market Cap: US$12.6m

Avalo Therapeutics Management

Management criteria checks 2/4

Avalo Therapeutics' CEO is Garry Neil, appointed in Feb 2022, has a tenure of 2.17 years. total yearly compensation is $909.11K, comprised of 52.2% salary and 47.8% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $732.35. The average tenure of the management team and the board of directors is 2.2 years and 2.6 years respectively.

Key information

Garry Neil

Chief executive officer

US$909.1k

Total compensation

CEO salary percentage52.2%
CEO tenure2.2yrs
CEO ownership0.006%
Management average tenure2.2yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007

Aug 01

Avalo Therapeutics announces one-for-twelve reverse stock split

Jul 06

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Aug 10
Is Cerecor (NASDAQ:CERC) A Risky Investment?

Cerecor enters into $35M debt financing agreement with Horizon Technology Finance

Jun 07

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Mar 10
What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Jan 18
Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Armistice Capital adds 2.5M Cerecor shares for $6.5M

Jan 13

Cerecor slumps 12% on stock and pre-funded warrants offering

Jan 07

Cerecor gains on CERC-002 data in mid-stage COVID-19 study

Jan 05

Cerecor trades higher as FDA accepts IND application for CERC-007

Dec 22

Dosing underway in Cerecor's early-stage CERC-007 study in multiple myeloma

Dec 16

CEO Compensation Analysis

How has Garry Neil's remuneration changed compared to Avalo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$909kUS$475k

-US$32m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$1mUS$469k

-US$42m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$1mUS$423k

-US$84m

Sep 30 2021n/an/a

-US$81m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$3mUS$373k

-US$64m

Compensation vs Market: Garry's total compensation ($USD909.11K) is above average for companies of similar size in the US market ($USD677.87K).

Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.

CEO

Garry Neil (69 yo)

2.2yrs

Tenure

US$909,112

Compensation

Dr. Garry A. Neil, M.D., serves as Independent Director of Celldex Therapeutics, Inc. since June 16, 2022. He has been President & Chief Executive Officer at Avalo Therapeutics, Inc. (formerly known as Cer...

Leadership Team

NamePositionTenureCompensationOwnership
Garry Neil
Chairman of the Board2.2yrsUS$909.11k0.0058%
$ 732.4
Christopher Sullivan
CFO & Head of Investor relations2.2yrsUS$523.65k0.00058%
$ 73.2
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Lisa Hegg
Senior Vice President of Program Management2.3yrsno datano data
Colleen Matkowski
Senior Vice President of Global Regulatory Affairs & Quality Assurance2.3yrsno datano data
Dino Miano
Senior Vice President of CMC & Technical Operations2.2yrsno datano data

2.2yrs

Average Tenure

63.5yo

Average Age

Experienced Management: AVTX's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Garry Neil
Chairman of the Board1.8yrsUS$909.11k0.0058%
$ 732.4
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Sol Barer
Special Advisor & Strategic Advisory Board2.8yrsUS$133.94kno data
Gilla Kaplan
Independent Director3.5yrsUS$60.12k0%
$ 0
Gunnar Magnus Severus Persson
Lead Independent Director12yrsUS$73.12k0%
$ 0
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Robert Lenox
Member of Scientific Advisory Boardno datano datano data
Anne Young
Member of Scientific Advisory Boardno datano datano data
Dennis Liotta
Member of Scientific Advisory Boardno datano datano data
June Almenoff
Independent Director2.4yrsUS$59.12k0%
$ 0
Mitchell Chan
Independent Director2.3yrsUS$60.12k0%
$ 0

2.6yrs

Average Tenure

69yo

Average Age

Experienced Board: AVTX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.